As AtheroGenics prepares to wrap up phase 3 trial sites for its lead atherosclerosis compound, small molecule AGI-1067, the future could suddenly become very bright for this tiny research company ...

AtheroGenics reveals more details about a phase 3 study for its lead compound. S&P 500 +---% | Stock Advisor +---% Join The Motley Fool. Accessibility Log In Help Accessibility Menu. Our ...